Pathology Core Facility Shared Resource

病理学核心设施共享资源

• 批准号: 9762031
• 负责人: Jian-Jun Wei
• 金额: $ 28.56万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9762031
• 关键词: AIDS related cancer; Accreditation; American; Applications Grants; Basic Science; Benign; Biological Markers; Blood; Body Fluids; CLIA certified; Cancer Center; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; Clinical Trials Unit; Collaborations; Collection; Communities; Comprehensive Cancer Center; Consent; Consult; Contracts; Core Facility; DNA; Data; Data Science; Databases; Development; Developmental Therapeutics Program; Division of Cancer Prevention; Ensure; Equipment and supply inventories; Evaluation; Formalin; Freezing; Fresh Tissue; Frozen Sections; Funding; Genes; Genetic screening method; Grant; Guidelines; Hematologic Neoplasms; Histocytochemistry; Histologic; Histology; Human; Image Analysis; Immunohistochemistry; Individual; Industry; Institutional Review Boards; Investigation; Laboratories; Malignant Neoplasms; Malignant neoplasm of prostate; Manuals; Manuscripts; Methods; Microarray Analysis; Mission; Modeling; Molecular; NCI Center for Cancer Research; Nanotechnology; Normal tissue morphology; Online Systems; Organoids; Paraffin Embedding; Pathologic; Pathologist; Pathology; Patients; Preparation; Primary Neoplasm; Procedures; Process; Protocols documentation; Publications; RNA; Records; Reproducibility; Research; Research Personnel; Resource Sharing; Resources; Role; Sampling; Services; Solid; Specimen; Standardization; System; Technology; Tissue Microarray; Tissues; Translational Research; Tumor Tissue; Work; anticancer research; base; biobank; biomarker development; blood product; cancer biomarkers; clinical database; college; digital pathology; epigenomics; human tissue; neoplastic; pre-clinical research; precision medicine; research study; therapy resistant; tool; tumor

ABSTRACT – PATHOLOGY CORE FACILITY The Pathology Core Facility (PCF) in the Robert H. Lurie Comprehensive Cancer Center (LCC) is a centralized, comprehensive facility that provides expertise in pathology and human tissue-based studies and is specifically dedicated to support the needs of the Lurie Cancer Center research community. The PCF provides access to high quality patient-derived biospecimens, routine histology laboratory tools and pathologic expertise to support basic and translational research and clinical trials. Each year, the PCF serves approximately 500 cancer research studies and clinical trials. In the last five years it has contributed to 253 scientific publications and 30 grant applications, including NCI-funded grants such as the SPORE in Prostate Cancer (P50 CA180995), the Center for Cancer Nanotechnology Excellence Center (U54 CA119341) and the Epigenomics Consortium for HIV-Associated Cancers (U54 CA221205). The PCF maintains rigorous standard operating procedures, laboratory methods, and technologies that ensure the highest quality services for a variety of established and emerging applications. The PCF is functionally divided into three units: the Core Lab, the Biorepository, and the Clinical Trials Unit. The Core Lab is accredited by the CAP (College of American Pathologists), and conducts all tasks in routine histology, immunohistochemistry for cancer biomarker development and digital pathology, and CLIA-compliant molecular work in DNA and RNA isolation from blood products and tissues. The Biorepository division procures, processes, stores and distributes well-characterized neoplastic and benign human tissues, blood products, and other body fluids from patients who have signed an IRB-approved consent. In addition, there is an organized systematic effort for generalized procurement and storage of most common solid cancers and hematologic malignancies, following NCI Best Practices for Biospecimen Resources guidelines. The Biorepository has developed detailed sample annotation, including pre-analytic variables, frozen section evaluation, specimen tracking, and quality controlled collection procedures, ensuring that clinically meaningful and reproducible data emerge from investigations that use PCF samples. The associated biorepository database is centralized and was created in collaboration with the Cancer Center’s Quantitative Data Sciences Core for easy access by investigators. The PCF-Clinical Trials Unit (PCF-CTU) consults with PIs and reviews all clinical protocols that involve collection of human tissue specimens. Their major responsibility is the procurement and processing of biospecimens for investigator-initiated clinical trials, industry-based clinical trials, and trials supported by a contract from the NCI Division of Cancer Prevention, as required per IRB approved protocols.

摘要 - 病理学核心设施 Robert H. Lurie综合癌症中心（LCC）的病理核心设施（PCF）是一个集中式的， 综合设施，可提供病理学和基于人体组织的研究专业知识，具体是 致力于支持Lurie癌症中心研究社区的需求。 PCF提供了对 高质量的患者衍生的生物测量，常规的组织学实验室工具和病理专业知识以支持 基本和翻译的研究和临床试验。每年，PCF大约为500个癌症服务 研究和临床试验。在过去的五年中，它为253个科学出版物和30个贡献了 赠款申请，包括NCI资助的赠款，例如前列腺癌中的孢子（P50 CA180995）， 癌症纳米技术中心卓越中心（U54 CA119341）和表观基因组学财团 与HIV相关的癌症（U54 CA221205）。 PCF保持严格的标准操作程序， 实验室方法和技术，可确保为各种已建立和 新兴申请。 PCF在功能上分为三个单元：核心实验室，生物座和临床试验单元。这 CORE LAB已获得CAP（美国病理学家学院）的认可，并在常规中执行所有任务 组织学，癌症生物标志物发育和数字病理学的免疫组织化学以及符合CLIA的癌症 从血液产物和组织中分离的DNA和RNA分离中的分子工作。生物座席采购， 过程，存储和分布良好的肿瘤和良性人体组织，血液产物和 来自已签署IRB批准同意的患者的其他体液。此外，还有一个有组织的 最常见的固体癌和血液学的全面采购和存储的系统努力 Malignancys，遵循NCI的生物测量资源指南的最佳实践。生物位具有 开发了详细的样品注释，包括预分析变量，冷冻部分评估，标本 跟踪和质量控制的收集程序，确保临床上有意义和可重复的数据 从使用PCF样品的投资中出现。相关的生物座数据库是集中的，并且 是与癌症中心的定量数据科学核心合作创建的，以便于 调查人员。具有PIS的PCF-Clinical试验单元（PCF-CTU）包含，并审查所有临床方案 涉及人类组织标本的收集。他们的主要责任是采购和处理 研究人员发起的临床试验，基于行业的临床试验以及由A支持 根据IRB批准的方案要求的NCI预防癌症预防司的合同。